Table 2 Baseline characteristics of patients diagnosed with acute heart failure syndrome with 30-day HF rehospitalization
Factors | Total (N = 84) | Non rehospitalization (N = 71) | Rehospitalization (N = 13) | P value |
|---|---|---|---|---|
Age (mean ± S.D.) | 69 ± 14 (19–97) | 70 ± 13 (34–97) | 66 ± 20 (19–92) | 0.535 |
Male gender | 40 (47.6%) | 36 (50.7%) | 4 (30.8%) | 0.186 |
Ethnicity (Thai) | 83 (98.8%) | 70 (98.6%) | 13 (100%) | 1.000 |
Past History | ||||
 Hx of HF | 60 (73.2%) | 48 (69.6%) | 12 (92.3%) | 0.169 |
 LVEF |  |  |  | 0.310 |
 No previous echo | 11 (16.9%) | 11 (20.4%) | 0 |  |
 pEF (> = 50%) | 34 (52.3%) | 28 (51.9%) | 6 (54.5%) |  |
 mrEF (40–49%) | 5 (7.7%) | 4 (7.4%) | 1 (9.1%) |  |
 rEF (< 40%) | 15 (23.1%) | 11 (20.4%) | 4 (36.4%) |  |
 Hx of HF hospitalization | 44 (67.7%) | 36 (64.3%) | 8 (88.9%) | 0.251 |
 Diabetes mellitus | 50 (59.5%) | 44 (62%) | 6 (46.2%) | 0.285 |
 Ischemic heart disease | 32 (38.1%) | 26 (36.6%) | 6 (46.2%) | 0.546 |
 Atrial fibrillation | 27 (32.1%) | 23 (32.4%) | 4 (30.8%) | 1.000 |
 Hypertension | 63 (75%) | 57 (80.3%) | 6 (46.2%) | 0.015 |
 Dyslipidemia | 47 (56%) | 43 (60.6%) | 4 (30.8%) | 0.047 |
 CKD at least stage III | 33 (39.3%) | 30 (42.2%) | 3 (23.1%) | 0.362 |
Treatment (Prior to admission) (mean ± S.D.)/median (IQR) | ||||
 Furosemide | 51 (60.7%) | 40 (56.3%) | 11 (84.6%) | 0.055 |
 Furosemide (mg/day) | 171.57 ± 272.78 40 (20–240) | 145 ± 237.17 40 (20–120) | 268.18 ± 373.60 60 (40–250) | 0.327 |
 Betablocker (BB) | 49 (58.3%) | 41 (57.7%) | 8 (61.5%) | 0.799 |
 ACEI | 11 (13.1%) | 10 (14.1%) | 1 (7.7%) | 1.000 |
 ARB | 15 (17.9%) | 13 (18.3%) | 2 (15.4%) | 1.000 |
 Spironolactone | 7 (8.3%) | 5 (7%) | 2 (15.4%) | 0.295 |
 Digoxin | 5 (6%) | 3 (4.2%) | 2 (15.4%) | 0.169 |
Treatment at discharge (mean ± S.D.)/median (IQR) | ||||
 Furosemide | 66 (78.6%) | 54 (76.1%) | 12 (92.3%) | 0.281 |
 Furosemide (mg/day) | 190.92 ± 276.18 80 (40–160) | 174.34 ± 269.93 80 (20–160) | 264.17 ± 303.6 120 (40–500) | 0.210 |
 HCTZ | 2 (2.4%) | 1 (1.4%) | 1 (7.7%) | 0.287 |
 Tolvaptan | 1 (1.2%) | 0 | 1 (7.7%) | 0.155 |
 Betablocker | 50 (59.5%) | 42 (59.2%) | 8 (61.5%) | 0.872 |
 ACEI | 9 (10.7%) | 8 (11.3%) | 1 (7.7%) | 1.000 |
 ARB | 8 (9.5%) | 8 (11.3%) | 0 | 0.347 |
 Spironolactone | 4 (4.8%) | 2 (2.8%) | 2 (15.4%) | 0.111 |
 Digoxin | 5 (6%) | 4 (5.6%) | 1 (7.7%) | 0.578 |